Merck KGaA Signs Cancer-MS Barter Deal With Japan's Ono

Merck Serono and Ono exchange rights to clinical programs in MS and cancer, with little cash changing hands

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Japan

More from Asia